Lantheus Holdings Inc
LNTH64.890USD
+0.030+0.05%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
4.30BMarket Cap
26.34P/E TTM
More Details of Lantheus Holdings Inc Company
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
Lantheus Holdings Inc Info
Ticker SymbolLNTH
Company nameLantheus Holdings Inc
IPO dateJun 25, 2015
CEOMarkison (Brian A)
Number of employees808
Security typeOrdinary Share
Fiscal year-endJun 25
Address331 Treble Cove Road
CityNORTH BILLERICA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01862
Phone19786718001
Websitehttps://www.lantheus.com/
Ticker SymbolLNTH
IPO dateJun 25, 2015
CEOMarkison (Brian A)
Company Executives of Lantheus Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Executive Chairman of the Board, Interim Executive Officer
Executive Chairman of the Board, Interim Executive Officer
599.01K
+14285.00%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
232.42K
+60654.00%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-17901.00%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
35.74K
+2537.00%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
23.36K
+2141.00%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
9.90K
+2537.00%
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Independent Director
Independent Director
3.10K
+2537.00%
Mr. Samuel R. (Sam) Leno
Mr. Samuel R. (Sam) Leno
Independent Director
Independent Director
--
--
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
--
--
Mr. Gary John Pruden
Mr. Gary John Pruden
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Executive Chairman of the Board, Interim Executive Officer
Executive Chairman of the Board, Interim Executive Officer
599.01K
+14285.00%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
232.42K
+60654.00%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-17901.00%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
35.74K
+2537.00%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
23.36K
+2141.00%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
9.90K
+2537.00%
Revenue Breakdown
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
PYLARIFY
240.62M
0.00%
DEFINITY
81.78M
0.00%
TechneLite
21.13M
0.00%
Neuraceq
20.44M
0.00%
Strategic partnerships and other
13.71M
0.00%
Other precision diagnostics
6.34M
0.00%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
PYLARIFY
240.62M
0.00%
DEFINITY
81.78M
0.00%
TechneLite
21.13M
0.00%
Neuraceq
20.44M
0.00%
Strategic partnerships and other
13.71M
0.00%
Other precision diagnostics
6.34M
0.00%
Shareholding Stats
Updated: Sun, Jan 11
Updated: Sun, Jan 11
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.00%
Janus Henderson Investors
10.08%
The Vanguard Group, Inc.
10.06%
Morgan Stanley & Co. LLC
5.55%
Farallon Capital Management, L.L.C.
5.24%
Other
58.08%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.00%
Janus Henderson Investors
10.08%
The Vanguard Group, Inc.
10.06%
Morgan Stanley & Co. LLC
5.55%
Farallon Capital Management, L.L.C.
5.24%
Other
58.08%
Shareholder Types
Shareholders
Proportion
Investment Advisor
51.50%
Investment Advisor/Hedge Fund
36.38%
Research Firm
8.68%
Hedge Fund
8.11%
Individual Investor
2.40%
Pension Fund
1.78%
Sovereign Wealth Fund
0.77%
Bank and Trust
0.72%
Family Office
0.13%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
1029
71.74M
108.19%
-15.56M
2025Q3
1018
78.96M
119.07%
-8.67M
2025Q2
1039
82.20M
120.88%
-4.84M
2025Q1
1066
83.20M
120.27%
-2.89M
2024Q4
1033
78.65M
114.86%
-4.64M
2024Q3
1003
73.69M
106.06%
-7.92M
2024Q2
959
71.82M
103.63%
-10.29M
2024Q1
912
71.21M
103.87%
-11.25M
2023Q4
868
73.50M
107.32%
-9.24M
2023Q3
828
74.80M
109.31%
-3.81M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
7.29M
11%
-208.45K
-2.78%
Sep 30, 2025
Janus Henderson Investors
6.68M
10.08%
-254.25K
-3.66%
Sep 30, 2025
The Vanguard Group, Inc.
6.92M
10.44%
+100.16K
+1.47%
Sep 30, 2025
Morgan Stanley & Co. LLC
3.68M
5.55%
+3.18M
+635.59%
Sep 30, 2025
Farallon Capital Management, L.L.C.
3.48M
5.24%
+161.00K
+4.85%
Sep 30, 2025
Fidelity Management & Research Company LLC
3.10M
4.68%
-1.03M
-24.93%
Sep 30, 2025
State Street Investment Management (US)
2.50M
3.77%
-61.59K
-2.41%
Sep 30, 2025
Geode Capital Management, L.L.C.
1.75M
2.65%
-22.43K
-1.26%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
1.37M
2.07%
-12.04K
-0.87%
Sep 30, 2025
Reinhart Partners, LLC
1.35M
2.03%
-55.90K
-3.98%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
State Street SPDR S&P Health Care Equipment ETF
1.96%
Invesco S&P MidCap 400 GARP ETF
1.69%
First Trust Small Cap US Equity Select ETF
1.07%
VictoryShares Small Cap Free Cash Flow ETF
0.93%
Invesco S&P MidCap 400 Pure Growth ETF
0.74%
Distillate Small/Mid Cash Flow ETF
0.66%
Pacer US Small Cap Cash Cows ETF
0.56%
Gotham 1000 Value ETF
0.5%
Invesco S&P MidCap Quality ETF
0.47%
Pacer US Cash Cows Growth ETF
0.47%
View more
State Street SPDR S&P Health Care Equipment ETF
Proportion1.96%
Invesco S&P MidCap 400 GARP ETF
Proportion1.69%
First Trust Small Cap US Equity Select ETF
Proportion1.07%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.93%
Invesco S&P MidCap 400 Pure Growth ETF
Proportion0.74%
Distillate Small/Mid Cash Flow ETF
Proportion0.66%
Pacer US Small Cap Cash Cows ETF
Proportion0.56%
Gotham 1000 Value ETF
Proportion0.5%
Invesco S&P MidCap Quality ETF
Proportion0.47%
Pacer US Cash Cows Growth ETF
Proportion0.47%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
